Compare Glenmark Pharma with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs LUPIN - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA LUPIN GLENMARK PHARMA/
LUPIN
 
P/E (TTM) x 14.1 25.6 55.2% View Chart
P/BV x 2.1 3.1 65.5% View Chart
Dividend Yield % 0.5 0.7 70.6%  

Financials

 GLENMARK PHARMA   LUPIN
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-21
LUPIN
Mar-21
GLENMARK PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs5731,122 51.0%   
Low Rs195576 33.9%   
Sales per share (Unadj.) Rs387.8334.2 116.0%  
Earnings per share (Unadj.) Rs34.427.0 127.2%  
Cash flow per share (Unadj.) Rs50.146.6 107.5%  
Dividends per share (Unadj.) Rs2.506.50 38.5%  
Avg Dividend yield %0.70.8 85.0%  
Book value per share (Unadj.) Rs249.6300.1 83.2%  
Shares outstanding (eoy) m282.17453.68 62.2%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x1.02.5 39.0%   
Avg P/E ratio x11.231.4 35.6%  
P/CF ratio (eoy) x7.718.2 42.1%  
Price / Book Value ratio x1.52.8 54.4%  
Dividend payout %7.324.0 30.2%   
Avg Mkt Cap Rs m108,353385,072 28.1%   
No. of employees `000NANA-   
Total wages/salary Rs m23,43728,259 82.9%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m109,439151,630 72.2%  
Other income Rs m5021,363 36.8%   
Total revenues Rs m109,941152,993 71.9%   
Gross profit Rs m21,28925,669 82.9%  
Depreciation Rs m4,4368,874 50.0%   
Interest Rs m3,5311,406 251.1%   
Profit before tax Rs m13,82516,751 82.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,1244,485 91.9%   
Profit after tax Rs m9,70112,266 79.1%  
Gross profit margin %19.516.9 114.9%  
Effective tax rate %29.826.8 111.4%   
Net profit margin %8.98.1 109.6%  
BALANCE SHEET DATA
Current assets Rs m73,596139,864 52.6%   
Current liabilities Rs m42,01084,361 49.8%   
Net working cap to sales %28.936.6 78.8%  
Current ratio x1.81.7 105.7%  
Inventory Days Days769 9.6%  
Debtors Days Days86108 79.6%  
Net fixed assets Rs m67,09394,439 71.0%   
Share capital Rs m282907 31.1%   
"Free" reserves Rs m70,148135,229 51.9%   
Net worth Rs m70,430136,136 51.7%   
Long term debt Rs m38,888161 24,124.2%   
Total assets Rs m140,689234,302 60.0%  
Interest coverage x4.912.9 38.1%   
Debt to equity ratio x0.60 46,630.3%  
Sales to assets ratio x0.80.6 120.2%   
Return on assets %9.45.8 161.2%  
Return on equity %13.89.0 152.9%  
Return on capital %15.913.3 119.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m35,75351,027 70.1%   
Fx outflow Rs m12,02321,081 57.0%   
Net fx Rs m23,72929,946 79.2%   
CASH FLOW
From Operations Rs m11,31218,218 62.1%  
From Investments Rs m-6,752-12,396 54.5%  
From Financial Activity Rs m-4,418-18,853 23.4%  
Net Cashflow Rs m278-13,031 -2.1%  

Share Holding

Indian Promoters % 46.5 46.6 99.8%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 41.2 40.3 102.2%  
FIIs % 34.4 19.0 181.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 53.5 53.1 100.7%  
Shareholders   85,475 299,620 28.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   KIMIA BIOSCIENCES  INDOCO REMEDIES  BAL PHARMA  MOREPEN LABS  SANOFI INDIA  



Today's Market

Indian Indices End Flat; Nestle, HDFC and ICICI Bank Among Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

GLENMARK PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Sep 6, 2021 | Updated on Sep 6, 2021

Here's an analysis of the annual report of GLENMARK PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY22); Net Profit Up 20.7% (Quarterly Result Update)

Aug 16, 2021 | Updated on Aug 16, 2021

For the quarter ended June 2021, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 20.7% YoY). Sales on the other hand came in at Rs 30 bn (up 26.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

5 Specialty Chemical Stocks that Turned Multibaggers in One Year(Views On News)

Sep 17, 2021

These specialty chemical stocks have surged 200% or more in the last year. Do you own any?

5 Indian Companies that are Leading the AI Race(Views On News)

Sep 9, 2021

During the pandemic, India reported the highest increase in the use of AI at 45% compared to other major economies. AI has potential to add US$90 bn to the Indian economy by 2025.

A Rare Buying Opportunity in an Exciting Stock(Profit Hunter)

Sep 16, 2021

Whether agriculture sector goes through a structural transformation or not, this agrochemical stock has a good chance of winning.

How to Create a Second Income from Trading(Profit Hunter)

Sep 10, 2021

My trading system that works in all kinds of markets.

5 Indian Companies with Over 7% in Dividend Yield(Views On News)

Sep 17, 2021

These stocks will give you better yields than bank deposits.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2021
Get our special report Multibagger Stocks Guide (2021 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Sep 22, 2021 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS